03:24 AM EDT, 04/28/2025 (MT Newswires) -- SpringWorks Therapeutics ( SWTX ) has agreed to be acquired by German technology firm Merck KGaA for $47 per share in cash, the companies said in a joint statement Monday.

The consideration represents about $3.9 billion in equity value, or $3.4 billion in enterprise value, for SprinWorks.

The deal is expected to close in H2, subject to regulatory approvals and customary closing conditions.